The current limited clinical benefit of rituximab despite successful CD19+ B-lymphocyte depletion in combination with a lower risk of SIEs among patients pertaining to the MOG+ group lend further support to the recent recognition of MOGAD as a distinct CNS demyelinating disease [52]. This evidence concerns the gene MOG and demyelinating disease of central nervous system.